Table 2 Dates of approval and reimbursement of pembrolizumab
Indication | FDA approval | NICE, England | PBAS, Australia | The National Advisory Committee for the Basket of Health Services, Israel |
|---|---|---|---|---|
2L after disease progression with chemotherapy with PD-L1 TPS ≥ 1% | October 2015 | January 2017 | (Rejected in 2016) | January 2018 |
1L monotherapy for TPS ≥ 50% | October 2016 | June 2017 | July 2018 (with PS 0–1) | January 2017 |
1L in combination with chemotherapy—non-squamous cell carcinoma | August 2018 | January 2019 | July 2019 (with PS 0–1) | January 2019 |
1L in combination with chemotherapy—squamous cell carcinoma | October 2018 | September 2019 | – | January 2019 |